EUCTR2006-001839-21-IT进行中（未招募）不适用
CHEMOTHERAPY PLUS LAPATINIB OR TRASTUZUMAB OR BOTH IN HER2 PRIMARY BREAST CANCER. A RANDOMIZED PHASE IIb STUDY WITH BIOMARKER EVALUATION. - CHERLOB
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •-histologically confirmed infiltrating primary breast cancer of 2.0 cm in largest clinical diameter -HER2 positive tumor either IHC 3 or FISH -Availability of tumor tissue suitable for biological and molecular examination before starting primary treatment -Age 18, 65 years -ECOG PS 0-1 -Normal organ and marrow function as defined below leukocytes 61619; 3000/ 61549;L absolute neutrophil count 61619; 61472;1,500/ 61549;L platelets 61619; 61472;100,000/ 61549;L total bilirubin within normal institutional limits AST SGOT /ALT SGPT 2.5 X institutional upper limit of normal Creatinine within normal institutional limits -Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan -Eligibility of patients receiving medications or substances known to affect, or with the potential to affect the activity or pharmacokinetics of lapatinib will be determined following review of their use by the Principal Investigator. A list of medications and substances known or with the potential to interact with CYP450 isoenzymes is provided in Section 3.7.4.2 Other concomitant treatments -The effects of lapatinib on the developing human fetus at the recommended therapeutic dose are unknown; women of child-bearing potential must agree to use adequate contraception hormonal or barrier method of birth control or abstinence prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately, the patient should be apprised of the potential hazard to the fetus and potential risk for loss of the pregnancy -Ability to understand and the willingness to sign a written informed consent document -Ability to swallow and retain oral medication
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Stage IIIB, IIIC, and inflammatory breast cancer -Stage IV breast cancer -Contraindication to the treatment with anthracycline, paclitaxel and/or trastuzumab -Prior treatment with chemotherapy, endocrine therapy or radiotherapy. Prior treatment with EGFR targeting therapies -Treatment with any other investigational agents, or with all herbal alternative medicines -History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib -Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements -Pregnancy or breastfeeding; breast feeding should be discontinued to be enrolled in the study -Women of childbearing potential that refusal to adopt adequate contraceptive measures -HIV-positive patients receiving combination anti-retroviral therapy -GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease e.g., Crohn s, ulcerative colitis -Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors See section 3.7.4.2 Other concomitant treatments
研究者
相似试验
进行中（未招募）
1 期
Chemotherapy plus Lapatinib (GW572016) or Trastuzumab or both in HER2+ Primary Breast Cancer. A Randomized Phase IIb study with Biomarker Evaluation - CHERLOBEUCTR2006-001839-21-GBGlaxoSmithKline Research and Development Limited
进行中（未招募）
不适用
A Randomized Phase IIb Study With Biomarker Evaluation (Cherlob) To Evaluate The Activity Of Different Combinations Of Lapatinib With Other Pre-Surgery Chemotherapy In Her2 Positive Operable Breast CancerEUCTR2006-001839-21-DEGlaxoSmithKline Reseacrh and Development Limited120
已完成
2 期
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast CancerNeoplasms, BreastNCT00429299GlaxoSmithKline121
招募中
2 期
Capecitabine / Cisplatin / Trastuzumab for previously untreated HER2 positive advanced gastric cancer. -Phase II studyuntreated HER2 positive advanced gastric cancerJPRN-UMIN000006591SGCSG: Shimane Gastroenterological Cancer Study Group25
已完成
2 期
Capecitabine / Cisplatin / Trastuzumab for previously untreated HER2 positive advanced gastric cancer.-Phase II studyuntreated HER2 positive advanced gastric cancerJPRN-UMIN000006590Herceptin Database of Shimane Prefecture25